These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34445495)

  • 1. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor.
    Lai ZY; Tsai KY; Chang SJ; Chuang YJ
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic investigating the cooperative lethal effect of EGFR and MDM2 inhibitors on ovarian carcinoma.
    Chang SJ; Liao EC; Yeo HY; Kuo WH; Chen HY; Tsai YT; Wei YS; Chen YJ; Wang YS; Li JM; Shih CC; Chan CH; Lai ZY; Chou HC; Chuang YJ; Chan HL
    Arch Biochem Biophys; 2018 Jun; 647():10-32. PubMed ID: 29655550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
    J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
    Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
    Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.
    Gao J; Xia R; Chen J; Gao J; Luo X; Ke C; Ren C; Li J; Mi Y
    Aging (Albany NY); 2020 Apr; 12(7):6240-6259. PubMed ID: 32276266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C iota promotes glycolysis via PI3K/AKT/mTOR signalling in high grade serous ovarian cancer.
    Tyagi K; Roy A; Mandal S
    Mol Biol Rep; 2024 Sep; 51(1):983. PubMed ID: 39276277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.
    Kapoor GS; Christie A; O'Rourke DM
    Cancer Biol Ther; 2007 Apr; 6(4):571-9. PubMed ID: 17457042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling.
    Li M; Hu M; Wang Y; Xia Z; Li Z; Li J; Zheng D; Zheng X; Xi M
    Biochem Biophys Res Commun; 2022 Dec; 637():348-357. PubMed ID: 36423381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
    Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
    Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
    Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
    Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGγ.
    Wang H; Bao W; Jiang F; Che Q; Chen Z; Wang F; Tong H; Dai C; He X; Liao Y; Liu B; Sun J; Wan X
    Cancer Lett; 2015 May; 360(2):269-79. PubMed ID: 25697482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.